Aurinia Pharmaceuticals Inc (AUPH)

[nferna]

Papp was the first author of the paper describing use of voclosporin for plaque psoriasis (back in the Isotechnika days)

In that study, patients were withdrawn from the trial if eGFR declined by 30%.

I believe that Sun is arguing that monitoring eGFR is an established method for screening for nephrotoxicity. Look, it was public knowledge even in 2008 when Papp was published. It is "prior art." Any physician competent to treat LN would be aware of this.

Further, even leaving Papp aside, they argue, it is well known that calcineurin inhibitors generally can cause nephrotoxicity.

So, the dose reductions in the patent are previously known and the patent should not be upheld.

This is my interpretation of the quote

Disclosure: I'm not an attorney, I'm a physician. Also, I'm an AUPH investor, so probably not too bright...